Castleark Management LLC Takes Position in IQVIA Holdings Inc. $IQV

Castleark Management LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, Holdings Channel.com reports. The firm purchased 22,580 shares of the medical research company’s stock, valued at approximately $3,851,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the fourth quarter worth approximately $25,000. Financial Freedom LLC purchased a new stake in IQVIA during the 1st quarter valued at $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the 1st quarter valued at $25,000. International Assets Investment Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at $27,000. Finally, Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter worth $27,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Robert W. Baird raised their target price on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Morgan Stanley restated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Mizuho increased their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Trading Up 2.3%

Shares of IQV stock opened at $212.76 on Tuesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $35.51 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 1.87 and a beta of 1.20. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The firm has a fifty day moving average price of $189.02 and a 200-day moving average price of $186.85.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.